Sunitinib offers significantly longer progression-free survival than everolimus for patients with metastatic non-clear cell renal cell carcinoma, phase II trial results indicate, but treatment effect appears to depend upon key patient characteristics.

See the original post:
Sunitinib versus everolimus trial highlights non-clear cell RCC patient response heterogeneity

Scroll to Top